TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05581004
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered as per the schedules specified in the respective arms.
Study: NCT04734418
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous pump injection.The initial dose of dexmedetomidine is 0.5 μg/kg/h.The drug dosage will be adjusted according to the subjects' intolerance relief (the treatment target is NIS ≤ 2), and the maximum dosage of dexmedetomidine is 1.0 μg/kg/h.
Study: NCT04851119
Drug: Tegavivint
Normalized name: Tegavivint
DrugBank: Tegavivint (DB17109)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06127043
Drug: Rosnilimab
Normalized name: Rosnilimab
DrugBank: Rosnilimab (DB18851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD-1 agonist antibody
Study: NCT06481228
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: BCL2 inhibitor
Study: NCT06481228
Drug: Olverembatinib
Normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TKI
Study: NCT05538910
Drug: Nicotine Patch
Normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Study drug: 7.5 mg Nicotine Patch which will be administered in a double blind, randomized manner
Study: NCT06253663
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05773274
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05773274
Drug: Lutetium Lu 177 Dotatate
Normalized name: Lutetium Lu 177 dotatate
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06518317
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short duration of aspirin (3 months) is compared to long duration of aspirin (12 months)
Study: NCT05609994
Drug: PEPIDH1M vaccine + vorasidenib
Normalized name: Vorasidenib
DrugBank: Vorasidenib (DB17097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids) intramuscularly into the deltoid muscle. Patients will then receive vorasidenib 40mg orally once a day for 28 days. After two cycles of 28-day vorasidenib and at the start of the 3rd cycle of vorasidenib, patients will receive the PEPIDH1M vaccine intradermally (i.d.) to alternating groin regions on the following schedule: vaccine #1, day 1; vaccine #2, day 15. The day before vaccine #1, patients will receive a vaccine site pre-conditioning injection of a single dose of Td toxoid. This will be administered twelve hours to one day prior to receiving PEPIDH1M vaccine i.d. to the RIGHT groin area. Vaccines #3 and #4 will be given on day 1 and day 15 of cycle 4. Starting on 6th cycle of 28-day vorasidenib, subjects will receive PEPIDH1M vaccine (i.d. to alternating groin regions) every 28 days on day 1 for vaccine #5-#12. Patients will receive up to a total of 14 cycles of vorasidenib.
Study: NCT05098574
Drug: Yaz
Normalized name: Yaz
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous treatment with 3mg drospirenone/ 0.02mg ethinyl estradiol for 12 weeks
Study: NCT05962632
Drug: Fluoride based varnish (Dentkist Charm Fill Varnish )
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical Fluoride varnish administrated professionally every 3 months in the clinic
Study: NCT05962632
Drug: pro care gel remineralizing agent
Normalized name: chloroxylenol Topical Gel [Caricia Care]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: topical remineralizing agent (Surface Pre-Reacted Glass ionomer filler SPRG based)SHOFU company
Study: NCT04433741
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin administered intravenously
Study: NCT05137288
Drug: Ondansetron , atropine and bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% ) with morphine 250mic and atropine sulphate 100 micwith total volume = 2.5 ml .~Patient received intrathecal hyperbaric bupivacaine ( 10 mg ) ( 2 ml 0.5% with 0.5 ml normal saline with morphine 250 mic ) with total volume = 2.5 ml with giving 4 mg IV ondansetron before anesthesia ( patients with body weight more than 80 Kg may need additional 4 mg IV ) .
Study: NCT05033587
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib a multi-target receptor tyrosine kinase inhibitor.
Study: NCT05033587
Drug: AK105
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AK105 is a humanized monoclonal antibody that specifically binds to PD-1.
Study: NCT05055518
Drug: APL-102 Capsules
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose escalation: A total of seven dose levels (1mg, 2mg, 3mg, 5mg, 7mg, 9mg and 11mg) are planned.~Dose extension: After RP2D determined, the RP2D dose level will be extended to enroll 6-10 subjects to further evaluated the safety and antitumor activity of APL-102.
Study: NCT05193201
Drug: recombinant human thrombopoietin injection
Normalized name: antihemophilic factor, human recombinant Injection [Recombinate]
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant human thrombopoietin: 15000 U subcutaneous injection once a day for 7 days
Study: NCT00080080
Drug: talabostat (PT-100) tablets
Normalized name: Talabostat
DrugBank: Talabostat (DB06182)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00080080
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05808946
Drug: Alpha-Lipoic Acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of ALA daily (given as two 600 mg capsules once daily)
Study: NCT05750056
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients received an intravenous bolus injection of lidocaine 1.5 mg/kg over 10 min before induction of anesthesia, followed by a continuous infusion of 2 mg/kg/h until the end of the procedure.
Study: NCT05750056
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An i.v. bolus injection of propofol 1 mg/kg was given to all patients. Propofol was then titrated if necessary to produce unconsciousness during the introduction of the endoscope. Afterward, the anesthesiologist determined the dose of propofol and titrated to effect.
Study: NCT05898672
Drug: Nirmatrelvir/ritonavir
Normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Twice daily oral doses of nirmatrelvir/ritonavir tablets
Study: NCT05849272
Drug: toludesvenlafaxine hydrochloride sustained-release tablets
Normalized name: bupropion
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: orally once a day
Study: NCT05129280
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab will be used as rescue therapy, in case of clinical presentation of cytokine release syndrome (CRS). Tocilizumab solution for infusion will be administered intravenously at 8 mg/kg for participants \>/= 30 kg or at 12 mg/kg for participants \< 30 kg.
Study: NCT06313502
Drug: 100gm HDAA
Normalized name: triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Initiation: Subjects will receive a test dose of ascorbate (15 gm), during screening period, prior to starting therapy.~Dose: After successfully completing the test dose, subjects will receive 100gm of ascorbate infusion. Dose modifications will not be made for weight or body surface area.~Administration: Infusion time is set to occur at 180 minutes +/-10 minutes but may be adjusted for subject comfort. The infusion rate should not exceed 500 mL/hour without consulting with PI. Changes in infusion rates should be recorded.
Study: NCT05137171
Drug: AK105 and anlotinib
Normalized name: cytarabine and daunorubicin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AK105(penpulimab): 200mg, every 3 weeks, 21 days as a treatment cycle;Anlotinib: 12mg, 2 weeks on/1 week off, 21 days as a treatment cycle;Treatment will continue until confirmed radiographic progression,unacceptable toxicity, investigator or patient decision to withdraw, non-adherence to treatment or trial procedures.
Study: NCT05798936
Drug: Polidocanol
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polidocanol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
Study: NCT05798936
Drug: Alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol is injected under complete aseptic conditions. Before the treatment the diameter and volume of each nodule is calculated. To prevent serious hemorrhage, vessels located along the approach route will be carefully evaluated by using Doppler US.
Study: NCT05295121
Drug: XC221 100 mg tablets
Normalized name: XC221
DrugBank: XC221 (DB16503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC221, 3 discrete doses separated by 7-day wash-out periods
Study: NCT05818956
Drug: TAK-227
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-227 capsules.
Study: NCT03706573
Drug: alpelisib
Normalized name: ALPELISIB
DrugBank: Alpelisib (DB12015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg and 200 mg film coated tablets administered orally once daily. Starting dose is 350 mg daily. Starting dose as a combination agent with endocrine partner is 300mg daily.
Study: NCT04336046
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupivacaine
Study: NCT06121609
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Exploring ED90 induced by remimazolam anesthesia in children of different age groups undergoing painless bidirectional endoscopy
Study: NCT05487040
Drug: PF-07321332 (nirmatrelvir)/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with Covid-19 infection and severe renal impairment. Capsule and tablet once a day by mouth.
Study: NCT05866029
Drug: Denosumab
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Active Comparator: 60mg of Denosumab treatment by subcutaneous injection
Study: NCT05866029
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide was sequentially treated with Denosumab
Study: NCT04964986
Drug: Apraglutide
Normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Study: NCT05735184
Drug: Ziftomenib
Normalized name: Ziftomenib
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT05735184
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral Administration
Study: NCT05735184
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous or Intravenous Administration
Study: NCT05735184
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Administration
Study: NCT05735184
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous Administration
Study: NCT06416358
Drug: ALMB-0168
Normalized name: ALMB-0168
DrugBank: ALMB-0168 (DB16926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALMB-0168 will be administered intravenously until either the disease progresses or intolerable toxicity occurs.
Study: NCT06067100
Drug: Indacaterol and Mometasonefluroate (low dose)
Normalized name: indacaterol and mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered 125 µg indacaterol + mometasonefluroate
Study: NCT06067100
Drug: Indacaterol and Mometasonefluroate (high dose)
Normalized name: indacaterol and mometasone
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants are administered 500 µg indacaterol + mometasonefluroate
Study: NCT06017609
Drug: JTT-861 Capsules
Normalized name: JTT-251
DrugBank: JTT-251 (DB18174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug capsules containing JTT-861
Study: NCT06650748
Drug: Dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib, oral administration, 125g each time, once daily, days 1-21, with a 28-day cycle (3 weeks on/1 week off). Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first; or after researcher's judgement, patient would no longer benefit from the treatment.
Study: NCT06650748
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg, oral, once daily (continuously), with a 28-day cycle. Continuous medication for 6 cycles, or disease progression, intolerable toxicity, withdrawal from the study for any reason or death, whichever occurs first. Refer to drug instructions for specific usage
Study: NCT06657391
Drug: recombinant humanized anti-CD25 monoclonal antibody
Normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention group received 4 doses of recombinant humanized anti-CD25 monoclonal antibody on days +7, +14, +28, and +42 after transplantation, with a recommended dose of 1 mg/kg.
Study: NCT06660823
Drug: L-thyroxine
Normalized name: L-Thyroxine
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients who show signs of delayed recovery defined as either prolonged ventilation for 48 hours or delayed conscious level recovery for 48 hours despite exclusion of muscle relaxants and/or sedative drugs. Those patients will undergo CT brain, CT chest and neurological examination to exclude structural damage as per institutional protocols. Also, metabolic profile screening including full kidney function, full liver function, electrolyte to exclude correctable metabolic abnormalities. and thyroid profile (TSH, free T3, free T4) sick euthyroid patients who are having normal FreeT3, normal Free T4, low TSH and low level of free T3 or freeT4 will be included in the study according lab reference.Daily assessment of conscious level according to Glasgow Coma Scale (GCS) and spontaneous breathing trial by ICU consultant (the investigator) till ICU discharge.~Patients will receive levothyroxine via Ryle, dose of 25 to 50 ug/ day according to BMI.
Study: NCT06658990
Drug: control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sufentanil is used after surgery
Study: NCT06660524
Drug: Sevelamer
Normalized name: Sevelamer
DrugBank: Sevelamer (DB00658)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevelamer is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guidelines for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Study: NCT06660524
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate is administered orally, and the administration strategy is implemented in accordance with the 2017 KDIGO Guideline and the 2019 Chinese Guideline for the Diagnosis and Treatment of Mineral and Bone Disorders in Chronic Kidney Disease.
Study: NCT06658054
Drug: Control (Standard treatment)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will receive standard ESPB with bupivacaine and normal saline
Study: NCT06658834
Drug: Dexamethasone Combined with romiplostim N01
Normalized name: Romiplostim
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dexamethasone (HD-DXM) at a dose of 40mg/d for 4 days constitutes one cycle. If there is no response on the 10th day, repeat it once. The administration can be either oral or intravenous. Meanwhile, romiplostim N01 is administered with an initial dose of 3µg/kg by subcutaneous injection once a week for up to 6 months.
Study: NCT06658834
Drug: Dexamethasone monotherapy
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (HD-DXM) 40mg/d × 4 days, one cycle. If there is no response on the 10th day, repeat once, administered either orally or intravenously.
Study: NCT06662175
Drug: Hyperbaric bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A (Unexposed) will received 2 ml of intrathecal bupivacaine
Study: NCT06662175
Drug: hyperbaric bupivacaine and dexmedetomidine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group B (Exposed) will receive a combination of bupivacaine and Dexmedetomidine infusion
Study: NCT06611345
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 1500 mg will be administrated via Intravenous (IV) infusion Once Every 3 weeks (Q3W) on day 1 of each cycle for up to 8 cycles. And then 1500 mg Once Every 4 weeks (Q4W) on day 1 of each cycle until confirmed progressive disease (PD).
Study: NCT06611345
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine 1000 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Study: NCT06611345
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 25 mg/m2 will be given on Days 1 and 8 of each cycle up to 8 cycles.
Study: NCT04726592
Drug: Clorazepate Dipotassium
Normalized name: Clorazepate Dipotassium
DrugBank: Clorazepic acid (DB00628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clorazepate Dipotassium : 20 mg intravenous injection
Study: NCT04726592
Drug: Metoclopramide
Normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide 10 mg IV
Study: NCT06659471
Drug: 0.76% Sodium Monofluorophosphate Dentifrice
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT06659471
Drug: 0.454% Stannous Fluoride Dentifrice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole mouth brushing with a toothpaste, twice daily for the duration of the study.
Study: NCT06660498
Drug: Pomalidomide 2 mg
Normalized name: pomalidomide 2 MG
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive pomalidomide 2 mg/d concurrently with aspirin 75 mg for three cycles, each consisting of 21 days on and a minimum of 7 days off.
Study: NCT06660498
Drug: Aspirin 75 mg
Normalized name: aspirin 75 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Auxiliary Medicinal Product
Study: NCT06660511
Drug: Disitamab Vedotin in Combination With Anlotinib Hydrochloride
Normalized name: Brentuximab Vedotin
DrugBank: Anlotinib (DB11885)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of Disitamab Vedotin(RC48) is 2.0 mg/kg iv q2w d1; The dose of Anlotinib Hydrochloride Capsules is 10mg po qd (recommended to be taken before meals and at the same time every day), taken orally continuously for 2 weeks and stopped for 1 week, with a treatment cycle of 21 days.~Main research endpoint: Objective response rate (ORR)~Secondary study endpoint:~1. Progression free survival (PFS)~2. Overall survival (OS)~3. Disease Control Rate (DCR)~4. Objective Duration of Response (DoR)
Study: NCT06660134
Drug: Glucagon-like peptide-1 receptor agonists (GLP 1 RA)
Normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In addition to the routine use of Antiarrhythmic Drugs (AADs) and anticoagulants, the strict weight reduction intervention group also uses GLP-1 receptor agonists for glycemic control and weight loss according to guidelines. This group receives a structured weight loss program, regular nutritional advice in accordance with current guidelines, and physical training assistance over a 12-month period. The intervention plan aims for a total weight loss of 10 kilograms while using GLP-1 receptor agonists.
Study: NCT06239220
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Epidermal growth factor receptor, via intravenous (into the vein) infusion per institutional standard of care.
Study: NCT06002906
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) is a safe, sterile, water-soluble molecule that binds to plasma proteins and can be injected intravenously. ICG will be injected intravenously based on the patient's weight prior to and after making the GJ anastomosis and a 10 mL bolus of normal saline will be immediately followed the injection of indocyanine green by an anesthesiologist. A subjective score of 1-5 for perfusion will be assigned by operating surgeons. The RYGB will then be completed by the operating surgeon in their routine fashion.
Study: NCT05858853
Drug: Human serum albumin
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug (human blood albumin injection) 10 g/ day for 14 days
Study: NCT05858853
Drug: Human serum albumin
Normalized name: Human serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control drug (human blood albumin injection) 20 g/ day for 7 days